Drugs / Stimulon QS-21
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06015724 Background | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Georgetown University | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stimulon QS-21 | “Stimulon QS-21 and Targovax TG01” NCT06015724 ↗ |